OxFORD Asset Management LLP Invests $2.03 Million in Acorda Therapeutics, Inc. (ACOR) Stock
OxFORD Asset Management LLP purchased a new position in shares of Acorda Therapeutics, Inc. (NASDAQ:ACOR) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 85,371 shares of the biopharmaceutical company’s stock, valued at approximately $2,025,000. OxFORD Asset Management LLP owned 0.18% of Acorda Therapeutics as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Piedmont Investment Advisors LLC purchased a new position in shares of Acorda Therapeutics in the 2nd quarter valued at approximately $199,000. Municipal Employees Retirement System of Michigan grew its stake in shares of Acorda Therapeutics by 3.9% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 10,960 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 410 shares during the last quarter. Laurion Capital Management LP purchased a new position in shares of Acorda Therapeutics in the 2nd quarter valued at approximately $219,000. Crossmark Global Holdings Inc. purchased a new position in shares of Acorda Therapeutics in the 3rd quarter valued at approximately $233,000. Finally, Aperio Group LLC grew its stake in shares of Acorda Therapeutics by 2.7% in the 2nd quarter. Aperio Group LLC now owns 12,972 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 343 shares during the last quarter.
ACOR has been the topic of several analyst reports. Cowen reiterated a “buy” rating and issued a $35.00 target price on shares of Acorda Therapeutics in a research note on Tuesday, August 29th. Zacks Investment Research downgraded Acorda Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 30th. Stifel Nicolaus reiterated a “buy” rating and issued a $26.00 target price (down from $30.00) on shares of Acorda Therapeutics in a research note on Thursday, August 31st. Goldman Sachs Group reiterated a “sell” rating and issued a $20.00 target price on shares of Acorda Therapeutics in a research note on Friday, October 6th. Finally, Janney Montgomery Scott reiterated a “hold” rating and issued a $18.00 target price on shares of Acorda Therapeutics in a research note on Wednesday, August 30th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Acorda Therapeutics has a consensus rating of “Hold” and a consensus target price of $21.47.
Shares of Acorda Therapeutics, Inc. (ACOR) opened at $20.70 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.40 and a current ratio of 2.77. Acorda Therapeutics, Inc. has a 12 month low of $13.60 and a 12 month high of $33.00.
Acorda Therapeutics (NASDAQ:ACOR) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.69 by ($0.26). Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. The business had revenue of $141.07 million during the quarter, compared to analysts’ expectations of $150.64 million. During the same quarter last year, the firm earned ($0.04) earnings per share. The firm’s quarterly revenue was up 4.0% compared to the same quarter last year. equities analysts predict that Acorda Therapeutics, Inc. will post -0.18 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/oxford-asset-management-llp-invests-2-03-million-in-acorda-therapeutics-inc-acor-stock/1764847.html.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.